Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma

JCOG0506

Hiroshi Ishii, Junji Furuse, Narikazu Boku, Takuji Okusaka, Masafumi Ikeda, Shinichi Ohkawa, Akira Fukutomi, Yasuo Hamamoto, Kenichi Nakamura, Haruhiko Fukuda

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objective: Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to be superior to chemotherapy alone in the gemcitabine era. The present multicentre phase II study was conducted to evaluate the efficacy and safety of Gem monotherapy against locally advanced pancreatic cancer in comparison with the historical data of chemoradiotherapy with 5-fluorouracil. Methods: Eligibility criteria included patients with histologically proven locally advanced pancreatic cancer, all lesions encompassed by a square of 15 cm on one side, no prior treatment, good performance status and adequate organ function. Gemcitabine was given intravenously at a dose of 1000 mg/m2 over 30 min on days 1, 8 and 15, repeated every 4 weeks. The primary endpoint was %1-year survival. Expected and threshold %1-year survival were 40 and 25%, respectively. Results: Between January 2006 and February 2007, 50 locally advanced pancreatic cancer patients were registered. The major grade 3-4 adverse events were neutropaenia (62%), thrombocytopaenia (18%), fatigue (12%) and infection-biliary tree (12%). Haematological toxicity was mostly transient and there was no episode of infection with grade 3-4 neutropaenia. Up to the final follow-up in February 2009, the median overall survival was 15.0 months with a %1-year survival of 64.0%. Conclusions: Gemcitabine monotherapy demonstrated far better survival than historical data for chemoradiotherapy with 5-fluorouracil with mild toxicities. Gemcitabine could be consider as a standard treatment for locally advanced pancreatic cancer. Trial Registration: This trial was registered in UMIN-CTR (http://www.umin.ac.jp/ctr/index-j. htm), identification number (C000000308).

Original languageEnglish
Article numberhyq011
Pages (from-to)573-579
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number6
DOIs
Publication statusPublished - 2010 Feb 25
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Chemoradiotherapy
Drug Therapy
Survival
Fluorouracil
Biliary Tract
Infection
Fatigue
Pancreatic Carcinoma
Safety
Therapeutics

Keywords

  • Chemoradiotherapy
  • Chemotherapy
  • Gemcitabine
  • Locally advanced pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Ishii, H., Furuse, J., Boku, N., Okusaka, T., Ikeda, M., Ohkawa, S., ... Fukuda, H. (2010). Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Japanese Journal of Clinical Oncology, 40(6), 573-579. [hyq011]. https://doi.org/10.1093/jjco/hyq011

Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma : JCOG0506. / Ishii, Hiroshi; Furuse, Junji; Boku, Narikazu; Okusaka, Takuji; Ikeda, Masafumi; Ohkawa, Shinichi; Fukutomi, Akira; Hamamoto, Yasuo; Nakamura, Kenichi; Fukuda, Haruhiko.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. 6, hyq011, 25.02.2010, p. 573-579.

Research output: Contribution to journalArticle

Ishii, H, Furuse, J, Boku, N, Okusaka, T, Ikeda, M, Ohkawa, S, Fukutomi, A, Hamamoto, Y, Nakamura, K & Fukuda, H 2010, 'Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506', Japanese Journal of Clinical Oncology, vol. 40, no. 6, hyq011, pp. 573-579. https://doi.org/10.1093/jjco/hyq011
Ishii, Hiroshi ; Furuse, Junji ; Boku, Narikazu ; Okusaka, Takuji ; Ikeda, Masafumi ; Ohkawa, Shinichi ; Fukutomi, Akira ; Hamamoto, Yasuo ; Nakamura, Kenichi ; Fukuda, Haruhiko. / Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma : JCOG0506. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. 6. pp. 573-579.
@article{7b5489272b3d4e38a5acd7625dc05eaf,
title = "Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506",
abstract = "Objective: Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to be superior to chemotherapy alone in the gemcitabine era. The present multicentre phase II study was conducted to evaluate the efficacy and safety of Gem monotherapy against locally advanced pancreatic cancer in comparison with the historical data of chemoradiotherapy with 5-fluorouracil. Methods: Eligibility criteria included patients with histologically proven locally advanced pancreatic cancer, all lesions encompassed by a square of 15 cm on one side, no prior treatment, good performance status and adequate organ function. Gemcitabine was given intravenously at a dose of 1000 mg/m2 over 30 min on days 1, 8 and 15, repeated every 4 weeks. The primary endpoint was {\%}1-year survival. Expected and threshold {\%}1-year survival were 40 and 25{\%}, respectively. Results: Between January 2006 and February 2007, 50 locally advanced pancreatic cancer patients were registered. The major grade 3-4 adverse events were neutropaenia (62{\%}), thrombocytopaenia (18{\%}), fatigue (12{\%}) and infection-biliary tree (12{\%}). Haematological toxicity was mostly transient and there was no episode of infection with grade 3-4 neutropaenia. Up to the final follow-up in February 2009, the median overall survival was 15.0 months with a {\%}1-year survival of 64.0{\%}. Conclusions: Gemcitabine monotherapy demonstrated far better survival than historical data for chemoradiotherapy with 5-fluorouracil with mild toxicities. Gemcitabine could be consider as a standard treatment for locally advanced pancreatic cancer. Trial Registration: This trial was registered in UMIN-CTR (http://www.umin.ac.jp/ctr/index-j. htm), identification number (C000000308).",
keywords = "Chemoradiotherapy, Chemotherapy, Gemcitabine, Locally advanced pancreatic cancer",
author = "Hiroshi Ishii and Junji Furuse and Narikazu Boku and Takuji Okusaka and Masafumi Ikeda and Shinichi Ohkawa and Akira Fukutomi and Yasuo Hamamoto and Kenichi Nakamura and Haruhiko Fukuda",
year = "2010",
month = "2",
day = "25",
doi = "10.1093/jjco/hyq011",
language = "English",
volume = "40",
pages = "573--579",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma

T2 - JCOG0506

AU - Ishii, Hiroshi

AU - Furuse, Junji

AU - Boku, Narikazu

AU - Okusaka, Takuji

AU - Ikeda, Masafumi

AU - Ohkawa, Shinichi

AU - Fukutomi, Akira

AU - Hamamoto, Yasuo

AU - Nakamura, Kenichi

AU - Fukuda, Haruhiko

PY - 2010/2/25

Y1 - 2010/2/25

N2 - Objective: Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to be superior to chemotherapy alone in the gemcitabine era. The present multicentre phase II study was conducted to evaluate the efficacy and safety of Gem monotherapy against locally advanced pancreatic cancer in comparison with the historical data of chemoradiotherapy with 5-fluorouracil. Methods: Eligibility criteria included patients with histologically proven locally advanced pancreatic cancer, all lesions encompassed by a square of 15 cm on one side, no prior treatment, good performance status and adequate organ function. Gemcitabine was given intravenously at a dose of 1000 mg/m2 over 30 min on days 1, 8 and 15, repeated every 4 weeks. The primary endpoint was %1-year survival. Expected and threshold %1-year survival were 40 and 25%, respectively. Results: Between January 2006 and February 2007, 50 locally advanced pancreatic cancer patients were registered. The major grade 3-4 adverse events were neutropaenia (62%), thrombocytopaenia (18%), fatigue (12%) and infection-biliary tree (12%). Haematological toxicity was mostly transient and there was no episode of infection with grade 3-4 neutropaenia. Up to the final follow-up in February 2009, the median overall survival was 15.0 months with a %1-year survival of 64.0%. Conclusions: Gemcitabine monotherapy demonstrated far better survival than historical data for chemoradiotherapy with 5-fluorouracil with mild toxicities. Gemcitabine could be consider as a standard treatment for locally advanced pancreatic cancer. Trial Registration: This trial was registered in UMIN-CTR (http://www.umin.ac.jp/ctr/index-j. htm), identification number (C000000308).

AB - Objective: Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been shown to be superior to chemotherapy alone in the gemcitabine era. The present multicentre phase II study was conducted to evaluate the efficacy and safety of Gem monotherapy against locally advanced pancreatic cancer in comparison with the historical data of chemoradiotherapy with 5-fluorouracil. Methods: Eligibility criteria included patients with histologically proven locally advanced pancreatic cancer, all lesions encompassed by a square of 15 cm on one side, no prior treatment, good performance status and adequate organ function. Gemcitabine was given intravenously at a dose of 1000 mg/m2 over 30 min on days 1, 8 and 15, repeated every 4 weeks. The primary endpoint was %1-year survival. Expected and threshold %1-year survival were 40 and 25%, respectively. Results: Between January 2006 and February 2007, 50 locally advanced pancreatic cancer patients were registered. The major grade 3-4 adverse events were neutropaenia (62%), thrombocytopaenia (18%), fatigue (12%) and infection-biliary tree (12%). Haematological toxicity was mostly transient and there was no episode of infection with grade 3-4 neutropaenia. Up to the final follow-up in February 2009, the median overall survival was 15.0 months with a %1-year survival of 64.0%. Conclusions: Gemcitabine monotherapy demonstrated far better survival than historical data for chemoradiotherapy with 5-fluorouracil with mild toxicities. Gemcitabine could be consider as a standard treatment for locally advanced pancreatic cancer. Trial Registration: This trial was registered in UMIN-CTR (http://www.umin.ac.jp/ctr/index-j. htm), identification number (C000000308).

KW - Chemoradiotherapy

KW - Chemotherapy

KW - Gemcitabine

KW - Locally advanced pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77953413803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953413803&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq011

DO - 10.1093/jjco/hyq011

M3 - Article

VL - 40

SP - 573

EP - 579

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

M1 - hyq011

ER -